Increased function of pronociceptive TRPV1 at the level of the joint in a rat model of osteoarthritis pain

Annals of the Rheumatic Diseases

Volumn 74, Issue 1, 2015, Pages 252-259

  Kelly, S ^a   Chapman, R J ^a   Woodhams, S ^a,b   Sagar, D R ^a,b   Turner, J ^a,b   Burston, J J ^a,b   Bullock, C ^a   Paton, K ^a   Huang, J ^a,b   Wong, A ^a   McWilliams, D F ^a   Okine, B N ^a,b   Barrett, D A ^a   Hathway, G J ^b   Walsh, D A ^a   Chapman, V ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 4 [3 (TRIFLUOROMETHYL) 2 PYRIDINYL] N [5 (TRIFLUOROMETHYL) 2 PYRIDINYL] 1 PIPERAZINECARBOXAMIDE; LIGAND; VANILLOID RECEPTOR 1; 4-(3-TRIFLUOROMETHYLPYRIDIN-2-YL)PIPERAZINE-1-CARBOXYLIC ACID (5-TRIFLUOROMETHYLPYRIDIN-2-YL)AMIDE; AMINOPYRIDINE DERIVATIVE; PIPERAZINE DERIVATIVE; TRPV1 PROTEIN, HUMAN; TRPV1 PROTEIN, RAT; VANILLOID RECEPTOR;

ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORE TEMPERATURE; DISEASE ACTIVITY; DISEASE MODEL; DRUG DOSAGE FORM COMPARISON; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KNEE OSTEOARTHRITIS; KNEE PAIN; LIQUID CHROMATOGRAPHY; MALE; MECHANICAL STIMULATION; NERVE CELL STIMULATION; NERVE CONDUCTION; NONHUMAN; PROTEIN FUNCTION; PROTEIN TARGETING; RAT; SENSORY NERVE; SPINAL CORD DORSAL HORN; SPINAL CORD NERVE CELL; TANDEM MASS SPECTROMETRY; THERMODYNAMICS; WEIGHT BEARING; WESTERN BLOTTING; AGED; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; ARTHRALGIA; BODY TEMPERATURE; DRUG EFFECTS; INTRAARTICULAR DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NOCICEPTIVE PAIN; OSTEOARTHRITIS; SPRAGUE DAWLEY RAT; SYNOVIUM;

12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; AGED; AMINOPYRIDINES; ANIMALS; ARTHRALGIA; BEHAVIOR, ANIMAL; BODY TEMPERATURE; CHROMATOGRAPHY, LIQUID; DISEASE MODELS, ANIMAL; HUMANS; INJECTIONS, INTRA-ARTICULAR; MIDDLE AGED; NOCICEPTIVE PAIN; OSTEOARTHRITIS; PIPERAZINES; RATS, SPRAGUE-DAWLEY; SYNOVIAL MEMBRANE; TANDEM MASS SPECTROMETRY; TRPV CATION CHANNELS;

EID: 84918588843     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203413     Document Type: Article

References (43)

1. Hinton R, Moody RL, Davis AW, et al. Osteoarthritis: diagnosis and therapeutic considerations. Am Fam Physic 2002;65:841-8.
2. Arden NK, Crozier S, Smith H, et al. Knee pain, knee osteoarthritis, and the risk of fracture. Arthritis Rheum 2006;55:610-15.
3. Crawford RW, Gie GA, Ling RS, et al. Diagnostic value of intra-articular anaesthetic in primary osteoarthritis of the hip. J bone Joint Surg 1998;80:279-81.
4. Creamer P, Hunt M, Dieppe P. Pain mechanisms in osteoarthritis of the knee: effect of intraarticular anesthetic. J Rheumatol 1996;23:1031-6.
5. Arendt-Nielsen L, Nie H, Laursen MB, et al. Sensitization in patients with painful knee osteoarthritis. Pain 2010;149:573-81.
6. Suokas AK, Walsh DA, McWilliams DF, et al. Quantitative sensory testing in painful osteoarthritis: a systematic review and meta-analysis. Osteo Cart 2012;20:1075-85.
7. Szolcsanyi J, Sandor Z. Multisteric TRPV1 nocisensor: a target for analgesics. Trends Pharma Sci 2012;33:646-55.
8. Brown BS, Keddy R, Zheng GZ, et al. Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists. Bioorgan Medical Chem 2008;16:8516-25.
9. Chu KL, Chandran P, Joshi SK, et al. TRPV1-related modulation of spinal neuronal activity and behavior in a rat model of osteoarthritic pain. Brain Res 2011;1369:158-66.
10. Honore P, Chandran P, Hernandez G, et al. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia. Pain 2009;142:27-35.
11. Honore P, Wismer CT, Mikusa J, et al. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J Pharmacol Exp Ther 2005;314:410-21.
12. Valdes AM, Spector TD. Genetic epidemiology of hip and knee osteoarthritis. Nat Rev Rheumatol 2011;7:23-32.
13. Fernihough J, Gentry C, Bevan S, et al. Regulation of calcitonin gene-related peptide and TRPV1 in a rat model of osteoarthritis. Neurosci Lett 2005;388:75-80.
14. Gavva NR, Treanor JJ, Garami A, et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 2008;136:202-10.
15. Romanovsky AA, Almeida MC, Garami A, et al. The transient receptor potential vanilloid-1 channel in thermoregulation: a thermosensor it is not. Pharmacol Rev 2009;61:228-61.
16. Garami A, Shimansky YP, Pakai E, et al. Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermia. J Neurosci 2010;30:1435-40.
17. Ayoub SS, Hunter JC, Simmons DL. Answering the burning question of how transient receptor potential vanilloid-1 channel antagonists cause unwanted hyperthermia. Pharmacol Rev 2009;61:225-7.
18. Steiner AA, Turek VF, Almeida MC, et al. Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors. J Neurosci 2007;27:7459-68.
19. Gavva NR, Bannon AW, Hovland DN Jr, et al. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J Pharmacol Exp Ther 2007;323:128-37.
20. Swanson DM, Dubin AE, Shah C, et al. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl) piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl) amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J Medicinal Chem 2005;48:1857-72.
21. Guzman RE, Evans MG, Bove S, et al. Mono-iodoacetate-induced histologic changes in subchondral bone and articular cartilage of rat femorotibial joints: an animal model of osteoarthritis. Toxicol Pathol 2003;31:619-24.
22. Sagar DR, Staniaszek LE, Okine BN, et al. Tonic modulation of spinal hyperexcitability by the endocannabinoid receptor system in a rat model of osteoarthritis pain. Arthritis Rheum 2010;62:3666-76.
23. Clayton NM, Oakley I, Thompson S, et al. Validation of the dual channel averager as an instrument of the measure of clinically relevant pain. Brit J Pharmacol 1997;120:219P.
24. Kelly S, Dunham JP, Murray F, et al. Spontaneous firing in C-fibers and increased mechanical sensitivity in A-fibers of knee joint-associated mechanoreceptive primary afferent neurones during MIA-induced osteoarthritis in the rat. Osteo Cart 2012;20:305-13.
25. Zhang D, Raghavan N, Chando T, et al. LC-MS/MS-based approach for obtaining exposure estimates of metabolites in early clinical trials using radioactive metabolites as reference standards. Drug Metab Letts 2007;1:293-8.
26. Haywood L, McWilliams DF, Pearson CI, et al. Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum 2003;48:2173-7.
27. Guo A, Vulchanova L, Wang J, et al. Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur J Neurosci 1999;11:946-58.
28. Dunham JP, Kelly S, Donaldson LF. Inflammation reduces mechanical thresholds in a population of transient receptor potential channel A1-expressing nociceptors in the rat. Eur J Neurosci 2008;27:3151-60.
29. Hendiani JA, Westlund KN, Lawand N. Mechanical sensation and pain thresholds in patients with chronic arthropathies. J Pain 2003;4:203-11.
30. Schuelert N, McDougall JJ. Electrophysiological evidence that the vasoactive intestinal peptide receptor antagonist VIP6-28 reduces nociception in an animal model of osteoarthritis. Osteo Cart 2006;14:1155-62.
31. Schuelert N, McDougall JJ. Grading of monosodium iodoacetate-induced osteoarthritis reveals a concentration-dependent sensitization of nociceptors in the knee joint of the rat. Neurosci Lett 2009;465:184-8.
32. De Schepper HU, De Winter BY, Van Nassauw L, et al. TRPV1 receptors on unmyelinated C-fibres mediate colitis-induced sensitization of pelvic afferent nerve fibres in rats. J Physiol 2008;586:5247-58.
33. Brederson JD, Chu KL, Reilly RM, et al. TRPV1 antagonist, A-889425, inhibits mechanotransmission in a subclass of rat primary afferent neurons following peripheral inflammation. Synapse 2012;66:187-95.
34. Fernandes ES, Fernandes MA, Keeble JE. The functions of TRPA1 and TRPV1: moving away from sensory nerves. Br J Pharmacol 2012;166:510-21.
35. Planells-Cases R, Valente P, Ferrer-Montiel A, et al. Complex regulation of TRPV1 and related thermo-TRPs: implications for therapeutic intervention. Advances Experi Med Biol 2011;704:491-515.
36. Engler A, Aeschlimann A, Simmen BR, et al. Expression of transient receptor potential vanilloid 1 (TRPV1) in synovial fibroblasts from patients with osteoarthritis and rheumatoid arthritis. Biochem Biophys Res Comm 2007;359:884-8.
37. Brenn D, Richter F, Schaible HG. Sensitization of unmyelinated sensory fibers of the joint nerve to mechanical stimuli by interleukin-6 in the rat: an inflammatory mechanism of joint pain. Arthritis Rheum 2007;56:351-9.
38. Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annual Rev Neurosci 2001;24:487-517.
39. Xie C, Wang DH. Inhibition of renin release by arachidonic acid metabolites, 12 (s)-HPETE and 12-HETE: role of TRPV1 channels. Endocrinology 2011;152:3811-19.
40. Wong GY, Gavva NR. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks. Brain Res Rev 2009;60:267-77.
41. Kelly S, Chapman V. Effects of peripheral nerve injury on functional spinal VR1 receptors. Neuroreport 2002;13:1147-50.
42. Kelly S, Chapman V. Spinal administration of capsazepine inhibits noxious evoked responses of dorsal horn neurons in non-inflamed and carrageenan inflamed rats. Brain Res 2002;935:103-8.
43. Donaldson LF. Unilateral arthritis: contralateral effects. Trends Neurosci 1999;22:495-6.